New York, October 01, 2014 -- Moody's Investors Service placed 21st Century Oncology, Inc.'s ("21st Century") ratings under review for upgrade, including the Caa2 Corporate Family Rating, Caa2-PD Probability of Default Rating, B1 ratings on the company's $100 million revolving credit facility and $90 million term loan, Caa2 rating on the company's existing $350 million 8.875% second lien notes, and Caa3 rating on the $380 million 9.875% subordinated notes. The company's speculative grade liquidity rating was changed to SGL-3 from SGL-4.
Vollständigen Artikel bei Moodys lesen
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.